Ray Dalio’s PTC Therapeutics PTCT Stock Holding History

Ray Dalio’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,229	Closed	-$1.23M	–	1180
2025 Q4	$1.23M	Buy	16,229 +4,291	+36%	+$312K	﹤0.01%	851
2025 Q3	$733K	Buy	+11,938	New	+$622K	﹤0.01%	881

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ray Dalio's PTCT Position: Q1 2026 in Review

Ray Dalio sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 16,229 shares — an estimated $1.23M sold.

Ray Dalio first reported a position in PTCT in Q3 2025 and held it in 2 quarters. The position peaked at $1.23M in Q4 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Ray Dalio reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
Ray Dalio sold 16,229 PTC Therapeutics shares in Q1 2026, an estimated $1.23M.
Ray Dalio first reported a position in PTC Therapeutics in Q3 2025 and held it in 2 quarters.
Ray Dalio's PTC Therapeutics position peaked at $1.23M in Q4 2025.
351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.